A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction
暂无分享,去创建一个
Gianluigi Savarese | L. Lund | W. Tay | G. Savarese | C. Lam | Wan Ting Tay | A. Koh | L. Benson | T. Teng | Lina Benson | Lars H Lund | O. Vedin | Carolyn S P Lam | Angela S Koh | Tiew Hwa Katherine Teng | Ola Vedin | Ulf Dahlstrom | U. Dahlstrom
[1] M. de Antonio,et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study , 2017, European journal of heart failure.
[2] R. Wachter,et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.
[3] Nancy M Albert,et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.
[4] G. Aurigemma,et al. Diastolic heart failure , 2004 .
[5] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[6] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[7] C. Yancy,et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. , 2016, JACC. Heart failure.
[8] C. O'connor,et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.
[9] L. Lund,et al. Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012 , 2016, European journal of heart failure.
[10] K. Tanabe,et al. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. , 2016, International journal of cardiology.
[11] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[12] L. Lund,et al. Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50% , 2015, Circulation. Heart failure.
[13] L. Friberg,et al. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. , 2014, JAMA.
[14] J. Gore,et al. Magnitude of and Prognostic Factors Associated With 1‐Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings , 2015, Journal of the American Heart Association.
[15] D. McManus,et al. Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. , 2014, The American journal of cardiology.
[16] G. Aurigemma,et al. Clinical practice. Diastolic heart failure. , 2004, The New England journal of medicine.
[17] D. Burkhoff,et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. , 2009, The American journal of cardiology.
[18] J. Ludvigsson,et al. External review and validation of the Swedish national inpatient register , 2011, BMC public health.
[19] J. Gardin,et al. Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.
[20] C. Lam,et al. Understanding Heart Failure With Mid-Range Ejection Fraction. , 2016, JACC. Heart failure.
[21] U. Dahlström,et al. Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.
[22] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[23] Deepak L. Bhatt,et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. , 2014, American heart journal.
[24] V. Roger,et al. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. , 2013, American journal of epidemiology.
[25] Sanjiv J Shah,et al. Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.
[26] L. Lund,et al. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. , 2015, European heart journal.
[27] C. Lam,et al. The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.
[28] L. Lund,et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. , 2012, JAMA.
[29] C. Yancy,et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.
[30] L. Lund,et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction , 2017, European journal of heart failure.
[31] Karl Swedberg,et al. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.
[32] L. Lund,et al. Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study , 2017, European journal of heart failure.